| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.50B | -69.6% |
| Gross profit | ¥-0.09B | — |
| Operating income | ¥-0.30B | — |
| Net income | ¥-0.27B | — |
| Gross margin | -19.1% | Net margin -55.4% |
| Revenue Q/Q | -10.2% | — |
The filing did not disclose a revenue breakdown for this period.
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.59B | 119.1% |
| R&D | ¥0.04B | 8.6% |
| SG&A | ¥0.09B | 18.2% |
| Tax & other | ¥-0.03B | -6.2% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
菲利华 ・ ST迪瑞 ・ 天和防务 ・ 飞凯材料 ・ 天利科技 ・ 劲拓股份 ・ 花园生物 ・ 宝色股份 ・ 汉宇集团 ・ 博济医药 ・ 科隆股份 ・ 九强生物
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies